Literature DB >> 16919623

Angiotensin AT4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I]Angiotensin IV only binds to the cystinyl aminopeptidase apo-enzyme.

Heidi Demaegdt1, Pieter-Jan Lenaerts, Julie Swales, Jean-Paul De Backer, Hilde Laeremans, Minh Tam Le, Ken Kersemans, Lotte K Vogel, Yvette Michotte, Patrick Vanderheyden, Georges Vauquelin.   

Abstract

Due to its high affinity for [(125)I]Angiotensin IV, cystinyl aminopeptidase (CAP) has recently been assigned as the 'angiotensin AT(4) receptor'. Since the aminopeptidase N (AP-N) activity is also susceptible to inhibition by Angiotensin IV, it might represent an additional target for this peptide. Based on [(125)I]Angiotensin IV binding and catalytic activity measurements, we compared the ligand interaction properties of recombinant human CAP and human AP-N. Both enzymes displayed distinct pharmacological profiles. Although their activity is inhibited by Angiotensin IV and LVV-hemorphin 7, both peptides are more potent CAP-inhibitors. On the other hand, substance P and l-methionine have a higher potency for AP-N. High affinity binding of [(125)I]Angiotensin IV to CAP occurs in the presence of chelators but not to AP-N in either the absence or presence of chelators. These differences were exploited to determine whether CAP and/or AP-N are present in different cell lines (CHO-K1, COS-7, HEK293, SK-N-MC and MDBK). We provide evidence that CAP predominates in these cell lines and that, comparatively, CHO-K1 cells display the highest level of this enzyme.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919623     DOI: 10.1016/j.ejphar.2006.07.005

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 3.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

4.  Translocation of the insulin-regulated aminopeptidase to the cell surface: detection by radioligand binding.

Authors:  H Demaegdt; L Smitz; J-P De Backer; M T Le; M Bauwens; E Szemenyei; G Tóth; Y Michotte; P Vanderheyden; G Vauquelin
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

5.  Peptide targeting of adenoviral vectors to augment tumor gene transfer.

Authors:  E N Ballard; V T Trinh; R T Hogg; R D Gerard
Journal:  Cancer Gene Ther       Date:  2012-05-18       Impact factor: 5.987

6.  Inhibition of Insulin-Regulated Aminopeptidase (IRAP) by Arylsulfonamides.

Authors:  Sanjay R Borhade; Ulrika Rosenström; Jonas Sävmarker; Thomas Lundbäck; Annika Jenmalm-Jensen; Kristmundur Sigmundsson; Hanna Axelsson; Fredrik Svensson; Vivek Konda; Christian Sköld; Mats Larhed; Mathias Hallberg
Journal:  ChemistryOpen       Date:  2014-11-21       Impact factor: 2.911

7.  Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers.

Authors:  Hanna Andersson; Mathias Hallberg
Journal:  Int J Hypertens       Date:  2012-12-04       Impact factor: 2.420

Review 8.  From Angiotensin IV to Small Peptidemimetics Inhibiting Insulin-Regulated Aminopeptidase.

Authors:  Mathias Hallberg; Mats Larhed
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.